Page 218 - Read Online
P. 218

Page 10 of 11                            Zhang et al. J Cancer Metastasis Treat 2018;4:16  I  http://dx.doi.org/10.20517/2394-4722.2018.01

               Conflicts of interest
               All authors declare no conflicts of interest.


               Patient consent
               Not applicable.


               Ethics approval
               Not applicable.


               Copyright
               © The Author(s) 2018.



               REFERENCES
               1.   Dong H, Strome SE, Salomao DR, Tamura J, Hirano F, Flie DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L.
                   Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
               2.   Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
               3.   Lu P, Youngblood BA, Austin JW, Mohammed AU, Butler R, Ahmed R, Boss JM. Blimp-1 represses CD8 T cell expression of PD-1
                   using a feed-forward transcriptional circuit during acute viral infection. J Exp Med 2014;211:515-27.
               4.   Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF, Wang D. Upregulation of PD-L1 and APE1 is
                   associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 2015;9:901-9.
               5.   Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin
                   Cancer Res 2015;21:976-84.
               6.   Xu F, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal
                   cell carcinoma: a meta-analysis. Int J Clin Exp Med 2015;8:14595-603.
               7.   Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a
                   poor prognosis for nasopharyngeal carcinoma. Mod Pathol 2010;23:1393-403.
               8.   Baptista MZ, Sarian LO, Derchain SF, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum
                   Pathol 2016;47:78-84.
               9.   Liu Y, Carlsson R, Ambjorn M, Hasan M, Badn W, Darabi A, Siesjo P. PD-L1 expression by neurons nearby tumors indicates better
                   prognosis in glioblastoma patients. J Neurosci 2013;33:14231-45.
               10.   Thierauf J, Veit JA, Affolter A, Bergmann C, Grunow J, Laban S, Lennerz JK, Grunmuller L, Mauch C, Plinkert P.K, Hess J,
                   Hoffmann TK. Identifcation and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and
                   neck. Melanoma Res 2015;25:503-9.
               11.   Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I,
                   Jöhrens K. Prognostic impact of programmed celldeath-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-
                   infltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016;7:1486-99.
               12.   Badoual C, Hans S, Merillon N, Ravel P, Benhamouda N, Levionnoks E, Besnier N, Gev A, Pere H, Tran T, Guerin CL, Chauvat A,
                   Dransart E, Alanio C, Albert S, Bruneval P, Gridman WH, Lenoine FM, Oudard S, Johannes L, Olive D, Brasnu D, Tartour E. PD-
                   1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res
                   2013;73:128-38.
               13.   Feng Z, Xiang LL, Hai TW, Zuo PW, Bao LH, Hai FZ, Xiao LW, Li L. Programmed cell death 1 expression in esophageal squamous
                   cell carcinoma and association with clinical characteristics. Indian J Cancer 2015;52:176-8.
               14.   Wu P, Wu D, Li LJ, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta analysis. PLoS One 2016;10:e0131403.
               15.   Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-
                   analyses. Eur J Epidemiol 2010;25:603-5.
               16.   Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-
                   analysis. Trials 2007;7:16-24.
               17.   Higgins JP, Thompson SG, Deeks JJ, Altaman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
               18.   DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
               19.   Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-
                   48.
               20.   Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
               21.   Egger M, Davey SG, Schneider M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
               22.   Zheng H, Liu X, Zhang JH, Shawn JR, Matthias W, Kong YX, Zhu LL, Zhu JJ, Monika J, Chandra PB. Expression of PD-1 on CD4+
                   T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 2016;7:56233-40.
               23.   Shen T, Zhou L, Shen H, Shi C, Jia S, Ding G, Cao L. Prognostic value of programmed cell death protein 1 expression on CD8+ T
                   lymphocytes in pancreatic cancer. Sci Rep 2017;7:7848-58.
   213   214   215   216   217   218   219   220   221   222   223